Join Drs Maureen McMahon and Michael Garshick as they discuss cardiovascular disease in patients with systemic lupus erythematosus, focusing on hidden risk and challenging clinical scenarios. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002126. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Systemic Lupus Erythematosus (SLE) https://emedicine.medscape.com/article/332244-overview Sore, Hot, and At Risk: The Emerging Specialty of Cardio-Rheumatology https://pubmed.ncbi.nlm.nih.gov/37232258/ The Bimodal Mortality Pattern of Systemic Lupus Erythematosus https://pubmed.ncbi.nlm.nih.gov/1251849/ About CDC-Funded Lupus Research https://www.cdc.gov/lupus/php/surveillance/index.html Traditional Framingham Risk Factors Fail to Fully Account for Accelerated Atherosclerosis in Systemic Lupus Erythematosus https://pubmed.ncbi.nlm.nih.gov/11665973/ Publisher Correction: Efferocytosis Drives a Tryptophan Metabolism Pathway in Macrophages to Promote Tissue Resolution https://pubmed.ncbi.nlm.nih.gov/39285251/ Cholesterol Efflux Pathways, Inflammation, and Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/34182846/ Role of Coronary Artery Calcium Score in the Primary Prevention of Cardiovascular Disease https://pubmed.ncbi.nlm.nih.gov/33947652/ Evaluation of Intima-Media Thickness and Arterial Stiffness as Early Ultrasound Biomarkers of Carotid Artery Atherosclerosis https://pubmed.ncbi.nlm.nih.gov/35362868/ Lupus Atherosclerosis Prevention Study (LAPS) https://pubmed.ncbi.nlm.nih.gov/21177297/ Colchicine in Acute Myocardial Infarction - CLEAR SYNERGY (OASIS 9) Colchicine https://www.acc.org/latest-in-cardiology/clinical-trials/2024/10/25/04/34/clear-synergy
--------
24:14
New Guidelines and the Lupus Nephritis Kidney Conundrum
Join Drs Maureen McMahon and Brad Rovin as they discuss the KDIGO, ACR and EULAR guidelines as they relate to lupus nephritis. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002125. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis https://rheumatology.org/press-releases/new-acr-guideline-summary-provides-guidance-to-screen-treat-and-manage-lupus-nephritis KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis https://pubmed.ncbi.nlm.nih.gov/38182286/ EULAR 2023 Recommendations for SLE Treatment: Synopsis for the Management of Lupus Nephritis: The European Renal Association-Immunonephrology Working Group (ERA-IWG) Perspective https://pubmed.ncbi.nlm.nih.gov/37881002/ Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33971155/ Podocytes https://pubmed.ncbi.nlm.nih.gov/26918173/ Can Podocytes Be Regenerated in Adults? https://pubmed.ncbi.nlm.nih.gov/28306565/ Prospective Observational Single-Centre Cohort Study to Evaluate the Effectiveness of Treating Lupus Nephritis With Rituximab and Mycophenolate Mofetil but No Oral Steroids https://pubmed.ncbi.nlm.nih.gov/23740227/ Safety of Kidney Biopsy When Performed as an Outpatient Procedure https://pubmed.ncbi.nlm.nih.gov/34077930/ Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis https://pubmed.ncbi.nlm.nih.gov/39927615/ Anifrolumab in Lupus Nephritis: Results From Second-Year Extension of a Randomised Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37607780/
--------
25:21
Lupus by the Numbers: What the Data Reveals
Join Drs Maureen McMahon and Peter Izmirly as they discuss lupus epidemiology, and why knowing the data is especially important for physicians on the frontlines of healthcare. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002123. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Population-Based Incidence and Prevalence of Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program https://pubmed.ncbi.nlm.nih.gov/24504809/ Update on Lupus Epidemiology: Advancing Health Disparities Research Through the Study of Minority Populations https://pubmed.ncbi.nlm.nih.gov/31436582/ Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries https://pubmed.ncbi.nlm.nih.gov/33474834/ 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus https://pubmed.ncbi.nlm.nih.gov/31383717/ CLUES Publications https://premier.ucsf.edu/california-lupus-epidemiology-study-clues Causes of Death Among Individuals With Systemic Lupus Erythematosus by Race and Ethnicity: A Population-Based Study https://pubmed.ncbi.nlm.nih.gov/35904969/ Prevalence of Cardiovascular Events in a Population-Based Registry of Patients With Systemic Lupus Erythematosus https://pubmed.ncbi.nlm.nih.gov/39272198/ Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project https://pubmed.ncbi.nlm.nih.gov/31115180
Über Medscape InDiscussion: Systemic Lupus Erythematosus
Listen to Medscape InDiscussion: Systemic Lupus Erythematosus, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002123. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.